Cholesterol Testing Services Market Size - By Test Type (Total Cholesterol, HDL, LDL, Triglyceride), Product Type (Testing Kits, Strips), Application (Cardiovascular Disease, Diabetes, Obesity), Age Group, Service Provider & Global Forecast, 2024 – 2032

Cholesterol Testing Services Market Size

Cholesterol Testing Services Market was valued at around USD 20.5 billion in 2023 and is estimated to grow at 8.1% CAGR from 2024 to 2032. Cholesterol testing services refer to diagnostic procedures and laboratory testing offered by healthcare providers or clinical laboratories to measure levels of cholesterol in a patient's blood. Cholesterol testing is an essential component of cardiovascular risk assessment and disease prevention. The procedure typically involves collecting a blood sample from the patient, which is then analyzed to determine the levels of various types of cholesterol, including low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides.
 

Moreover, increasing use of cardiac arrhythmia monitoring devices, rising adoption of cardiology information system (market size is estimated to account for USD 2.4 billion by the end of year 2032), growing awareness about prediabetes, rising healthcare expenditure globally, government initiatives and funding, and increasing education & awareness, are the stimulating factors fostering the growth of the market.
 

Cholesterol Testing Services Market Trends

The rising prevalence of cardiovascular diseases is a significant driver for cholesterol testing services industry. Risk factors for cardiovascular disease (CVD), including pulmonary arterial hypertension, hypercholesterolemia, diabetes, and smoking, are becoming increasingly prevalent worldwide.  
 

• According to the American Heart Association, in 2023, the prevalence of CVD was 607.64 million cases in 2020, an increase of 29.01% compared with 2010. Further, as per the Centers for Disease Control and Prevention, in 2023, coronary heart disease is the most common type of heart disease that killed 375,476 people in 2022.
   
• Similarly, as per the American Heart Association (AHA) report, in 2023, valvular heart disease affects about 2.5% of the U.S. population. Further, the prevalence is much higher in older adults, with around 13% of people born before 1943 having valvular heart disease.
   
• Further, according to the World Health Organization (WHO), in 2023, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year.
   
• Early detection of risk factors such as dyslipidemia (abnormal cholesterol levels) is crucial for preventing the development and progression of CVD. Cholesterol testing helps identify individuals at risk of cardiovascular events, enabling healthcare providers to initiate preventive measures such as lifestyle modifications, medication therapy, and cardiovascular risk reduction strategies.
   

Cholesterol Testing Services Market Analysis

Based on test type, the market is segmented into total cholesterol tests, high density lipoprotein (HDL) cholesterol tests, low density lipoprotein (LDL) cholesterol tests, triglyceride tests, and other tests. The total cholesterol tests segment is exceeded USD 14.4 billion by 2032.
 

• Total cholesterol tests provide a comprehensive measure of the total amount of cholesterol present in the blood, including both low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and other lipoproteins. This single test gives healthcare providers an overall picture of a patient's lipid profile and is valuable for assessing cardiovascular risk and guiding treatment decisions.
   
• The test has been a cornerstone of cardiovascular risk assessment for decades. It is a widely accepted and standardized test used in routine health screenings, preventive care, and disease management. Healthcare providers rely on total cholesterol levels as an essential component of lipid profiling and cardiovascular risk stratification in patients.
   
• Furthermore, these tests are relatively simple and easy to perform, requiring a single blood sample and standardized laboratory assays. They can be integrated into routine health check-ups, wellness programs, and population-based screening initiatives without the need for specialized equipment or expertise. This simplicity and convenience contribute to the widespread adoption of total cholesterol testing in clinical practice.
   
• Elevated total cholesterol levels, particularly when accompanied by abnormal levels of LDL cholesterol and other lipid fractions, indicate an increased risk of atherosclerosis, heart disease, and stroke. Consequently, total cholesterol testing helps healthcare providers identify individuals who may benefit from further evaluation, lifestyle modifications, or pharmacological interventions to reduce cardiovascular risk, thereby accelerating the segmental growth.
   

Based on product type, the cholesterol testing services market is divided into testing kits, testing strips, and other product types. The testing kits segment was valued at USD 9.2 billion in 2023.

• Testing kits offer convenience by allowing individuals to test their cholesterol levels from the comfort of their own homes. This convenience eliminates the need for a visit to a healthcare facility, saving time and effort for users.
   
• Increase in cholesterol screening further escalated the adoption of these kits. For instance, according to the National Institutes of Health, 2023, there has more than 10% increased in the cholesterol screening rates in the last decade.
   
• Further, testing kits are widely available for purchase online, over the counter at pharmacies, and in retail stores. This accessibility makes it easy for individuals to obtain testing kits without the need for a prescription or a healthcare provider's visit.
   
• Testing kits typically provide rapid results, allowing individuals to obtain their cholesterol measurements quickly, sometimes within minutes. This rapid turnaround time enables users to take immediate action based on their cholesterol levels and make informed decisions about their diet, lifestyle, and healthcare management.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on application, the cholesterol testing services market is divided into cardiovascular diseases, diabetes, obesity, hyperlipidemia, and other applications. Cardiovascular diseases segment accounted for a market share of 33.4% in 2023.
 

• Cardiovascular diseases, including heart disease and stroke, are leading causes of morbidity and mortality worldwide. High cholesterol levels are a major risk factor for the development of CVDs. As a result, there is a significant demand for cholesterol testing services among individuals at risk of or already diagnosed with cardiovascular diseases.
   
• For instance, according to the Heart Foundation, in 2024, cardiovascular disease accounts for one in four of all deaths, claiming the life of one person every 12 minutes.
   
• Further, according to the latest report of European Commission, in 2024, cardiovascular diseases are the leading cause of death in the EU, mainly concerning heart attacks and strokes.
   
• The global population is aging leading to an increase in the prevalence of cardiovascular diseases. Older adults are more likely to have elevated cholesterol levels and other risk factors for heart disease, driving demand for cholesterol testing services in this demographic group.
   

Based on age group, the cholesterol testing services market is segmented into geriatric, adult, and pediatric. The geriatric segment held a market size of USD 9.6 in the year 2023.
 

• Cholesterol levels tend to change with age with older adults often experiencing higher levels of low-density lipoprotein (LDL) cholesterol, commonly known as "bad" cholesterol. Additionally, age-related changes in metabolism, hormonal balance, and lifestyle factors can contribute to dyslipidemia (abnormal lipid levels) and an increased risk of CVDs, necessitating regular cholesterol testing in geriatric individuals.
   
• Increasing geriatric population is also a contributing factor. With more people living with these disorders there’s a substantial pool of the proper management and testing services.
   
• For instance, according to the United Nations, in 2019, 8.5% of people worldwide (617 million) were aged 65 and over. By 2050, this is projected to nearly double to 16% of the global population.
   
• Further, healthcare organizations and professional societies, such as the American Heart Association (AHA) and the American College of Cardiology (ACC), recommend routine cholesterol screening for older adults as part of cardiovascular risk assessment and preventive care. Thus, escalating the growth of the market.
   

Based on service provider, the cholesterol testing services market is segmented into hospitals and clinics, diagnostic laboratories, ambulatory care centers, and other service providers. The hospitals and clinics segment is expected to reach USD 15.9 by 2032.
 

• Hospitals and clinics are comprehensive healthcare facilities equipped with a wide range of medical services, including diagnostic testing capabilities. They often have well-established laboratory facilities equipped with advanced cholesterol testing equipment and trained personnel to perform cholesterol tests efficiently and accurately.
   
• They typically serve a large volume of patients, including individuals seeking routine health check-ups, preventive screenings, and management of chronic conditions such as cardiovascular disease.
   
• Further, cholesterol testing is a routine part of health assessments and cardiovascular risk assessments conducted in hospitals and clinics, contributing to a high volume of cholesterol tests performed in these settings.
   
• Hospitals often house specialized departments or units focused on cardiology, internal medicine, endocrinology, and other medical specialties that manage patients with cardiovascular risk factors, including high cholesterol levels. Patients seeking specialized care for cholesterol management are more likely to undergo cholesterol testing in hospitals and clinics where they can access comprehensive medical services and expertise.
   

The U.S. cholesterol testing services market is anticipated to grow at CAGR of 7.8% during 2024 to 2032.
 

• Cardiovascular disease (CVD remains a leading cause of morbidity and mortality in the U.S. High cholesterol levels are a major risk factor for CVD, leading to a high demand for cholesterol testing services among the population.
   
• For instance, according to the National Institutes of Health, in 2022, CVD accounted for 928,741 deaths in the U.S., with coronary heart disease (CHD) being the leading cause of CVD-related deaths at 41.2%, followed by stroke at 17.3%.
   

Germany cholesterol testing services market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country has a universal healthcare system that provides comprehensive health coverage to its residents through statutory health insurance (SHI) funds or private health insurance (PHI) companies.
   
• Cholesterol testing services are typically covered by health insurance plans, ensuring widespread access and affordability for patients seeking preventive screenings or diagnostic evaluations.
   

Japan cholesterol testing services market is expected to grow significantly over the years.
 

• Japan places a strong emphasis on preventive medicine and public health initiatives aimed at reducing the burden of chronic diseases and promoting healthy aging. Regular cholesterol screening is recommended as part of routine health check-ups, particularly for middle-aged and older adults, to identify individuals at risk of cardiovascular disease and initiate appropriate interventions.
   
• Further, the country is known for its technological innovation and contributions to medical research and healthcare delivery. The country's healthcare industry invests in advanced diagnostic technologies, laboratory equipment, and assay platforms for cholesterol testing, ensuring accurate, reliable, and efficient test results for patients and healthcare providers.
   

UAE cholesterol testing services market is anticipated to witness lucrative growth between 2024 – 2032.
 

• UAE is at the forefront of technological innovation in healthcare, with investments in digital health solutions, telemedicine platforms, and advanced diagnostic technologies.
   
• Cholesterol testing services benefit from technological advancements such as point-of-care testing devices, automated laboratory analyzers, and digital health platforms, which enhance the accuracy, efficiency, and accessibility of testing services.
   

Cholesterol Testing Services Market Share

The cholesterol testing services industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive testing services with improved efficiency and affordability. This includes advancements in reading, materials used, data reporting, sensor design, and customization. Competition is driven by factors such as the quality, reliability, performance, cost, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.
 

Cholesterol Testing Services Market Companies

Some of the eminent market participants operating in the cholesterol testing services industry include:

• Abbott Laboratories
• Accu Reference Medical Lab, LLC
• Atherotech Diagnostics Lab
• Bio-Reference Laboratories, Inc.
• Boston Heart Diagnostics Corporation
• Cell Biolabs Inc.
• Clinical Reference Laboratory, Inc.
• Eurofins Scientific
• Mayo Clinic Laboratories
• Quest Diagnostics Incorporated
• Randox Laboratories Limited
• Sonic Healthcare Limited
• SpectraCell Laboratories Inc.
• SYNLAB Holding Deutschland GmbH
• Thermo Fisher Scientific Inc.
   

Cholesterol Testing Services Industry News

• In March 2023, Quest Diagnostics announced that it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light. This acquisition enhanced the testing services of the company and helped to increase the sales.
   
• In November 2022, SYNLAB Holding Deutschland GmbH partnered with Guy's & St Thomas' NHS Foundation Trust and King's College Hospital NHS Foundation Trust with an agreement to act as a joint venture in respect of the Southeast London Pathology Procurement. This collaboration expanded the cholesterol testing services and cardiology related tests of the company. Thus, helped to generate revenue.
   

This cholesterol testing services market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Total cholesterol tests
• High density lipoprotein (HDL) cholesterol tests
• Low density lipoprotein (LDL) cholesterol tests
• Triglyceride tests
• Other tests

Market, By Product Type

• Testing kits
• Testing strips
• Other product types

Market, By Application

• Cardiovascular diseases
• Diabetes
• Obesity
• Hyperlipidemia
• Other applications

Market, By Age Group

• Geriatric
• Adult
• Pediatric

Market, By Service Provider

• Hospitals and clinics
• Diagnostic laboratories
• Ambulatory care centers
• Other service providers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa